Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

nal Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's RSV vaccine program.  This grant will be used to further advance the novel pediatric RSV vaccine.
 
  • Promising data were presented on GenVec's RSV vaccine program at the 8th Annual International Respiratory Syncytial Virus Symposium, demonstrating that GenVec's pre-clinical, universal RSV vaccine candidate is highly immunogenic and produces durable and broad protection from a single intramuscular administration.  Protection in cotton rat and mouse models was characterized by functional RSV neutralizing antibodies and no disease potentiation was observed.
     
  • Encouraging preclinical proof of concept data generated in non-human primates involving GenVec's RSV vaccine program were presented at the Keystone Symposia 2012 Meeting on Viral Immunity and Host Gene Influence.  GenVec's vaccine technology induced neutralizing antibody and significant T-cell responses with a single administration.  The immune responses were consistent with protective responses without disease potentiation, and multiple administrations increased the neutralizing antibody responses.
  • HSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against herpes simplex virus (HSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
  • Data were presented on GenVec's HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination.  The Company disclosed that a single administration of its genetic vaccine was effective against HSV2 in two industry-accepted HSV disease models.
  • Mala
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
    (Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
    (Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
    Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
    ... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
    ... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
    Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
    (Date:8/31/2014)... Franklin, TN (PRWEB) August 31, 2014 ... continuing education course provides an in-depth analysis ... and treatment of selected shoulder complex conditions. Over ... utilizing case studies, clinical reasoning and problem solving ... algorithm-based examination format for the special tests of ...
    (Date:8/31/2014)... 31 August 2014: Drinking tea reduces non-cardiovascular mortality by ... at ESC Congress today by Professor Nicolas Danchin from ... choose between tea or coffee it,s probably better to ... our way of life. Their effects on cardiovascular (CV) ... divergent results. We investigated the effects of coffee and ...
    (Date:8/30/2014)... 2014: A new batteryless cardiac pacemaker based on ... was presented at ESC Congress 2014 today by ... not require battery replacement. , Mr Zurbuchen, a ... ARTORG, University of Bern, Switzerland, said: "Batteries are ... they reach a critically low energy level, physicians ...
    (Date:8/30/2014)... MN (PRWEB) August 31, 2014 As ... in home renovation, especially spa style bathrooms and in-home ... (NASS) has observed an increase in interest not only ... the history, culture and health benefits of sauna. ... Finnleo , the North American Sauna Society provides a ...
    (Date:8/30/2014)... 2014 UWDress.com, a distinguished wedding dress supplier, ... first range of fashionable outfits. Recently, the company has unveiled ... As an autumn special offer, all these brand new products ... , “We are excited to unveil the new and ... high quality products are available at low prices now. The ...
    Breaking Medicine News(10 mins):Health News:North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2
    ... 6 In a newly-published special supplement, the Journal ... prevent and treat venous thromboembolism (VTE), a major cause ... Lippincott Williams & Wilkins (LWW) is publishing ... that includes both the common medical condition of deep ...
    ... statement in observance of Pancreatic Cancer Awareness Month , WASHINGTON, ... yet it is the fourth leading cause of death by cancer ... be diagnosed with the disease and more than 35,000 will die ... find a cure for pancreatic cancer researchers have to know more ...
    ... role in boosting memories -- or forgetting them, researchers say ... remember the first time you smelled a type of flower? ... brain might. , In the study, published online Nov. ... objects to adult study participants. They paired the objects with ...
    ... small group of patients with severe Graves, eye disease ... vision following treatment with the drug rituximab. Inflammation ... were significantly reduced. The same patients had not previously ... disease. Raymond S. Douglas, M.D., Ph.D., an oculoplastics ...
    ... TORONTO, On November 6, 2009 Researchers at St. ... fire services across Ontario found that a bystander who attempts ... 50 per cent. But Dr. Laurie Morrison and the research ... per cent of bystanders in Toronto are willing to help, ...
    ... , COLUMBUS, Ohio, Nov. 6 The Ohio Association of ... health care premiums and less robust benefits if proposals being ... were to become law. , If the reforms proposed by ... in Ohio would increase 60% over five years in the ...
    Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Researchers find new way to attack inflammation in Graves' eye disease 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Congressional Health Care Reform Proposals Will Make Health Care More Expensive, Less Robust for Ohioans 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: